This reversal was sustained with a bolus plus an infusion of andexanet; the mean plasma concentrations of unbound apixaban and rivaroxaban were reduced by a significantly greater amount with ...

The primary efficacy endpoint was the reversal of apixaban-induced anti-Factor Xa activity (mean change from baseline at 2 or 5 minutes after the end of the bolus).

Currently, supportive care is the mainstay of therapy for rapid reversal. The half-lives of apixaban, rivaroxaban and edoxaban are 5 to 14 hours, although the full anticoagulant effect may persist ...

RELATED: Pradaxa Reversal Agent Works Within Minutes in Phase 3 Study Results demonstrated that after administrating a bolus of andexanet alfa, the anticoagulant activity of apixaban, was reversed ...

Guidelines for VTE Prophylaxis in Nonsurgical Patients Issued Different factor concentrates can reverse some of the alterations in hemostasis attributed to apixaban. (HealthDay News) – Different ...

ZUG, Switzerland, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Covis Pharma GmbH (“Covis”) and Norgine B.V. (“Norgine”) today announced data demonstrating the investigational anticoagulant reversal ...

– Breakthrough Product is a Major Advance in the Treatment of Patients Hospitalized with Life-Threatening Bleeding – – Company to Host Conference Call on Friday, May 4, 2018 at 8:30 a.m. ET ...

Reversal of apixaban anticoagulation by 4-factor prothrombin complex concentrates in healthy subjects: a randomized 3-period crossover study. J. Thromb. Haemost. 15, 2125–2137 (2017).

February 10, 2011 (Los Angeles, California) — Final results of the AVERROES trial confirm that apixaban (Pfizer/Bristol-Myers Squibb), a still-investigational factor Xa inhibitor, reduced the ...

Rivaroxaban (Xarelto) was also associated with higher risk than apixaban (42.94 vs 20.05 per 1,000 person-years, HR 2.15, 95% ...